CRL focused on CMC; no clinical issues relating to etripamil raised $69.7M in cash, cash equivalents and short-term investments as of December 31, 2024 MONTREAL and CHARLOTTE, N.C., March 28, 2025 ...
In 2023, the FDA rejected a small pharmaceutical company's new drug application (NDA ... Whether advocating CMC strategy, directing CMC operations, or developing CMC submission content that ...
CRL focused on CMC; no clinical issues relating to etripamil raised $69.7M in cash, cash equivalents and short-term investments as of December 31, 2024 MONTREAL and CHARLOTTE, N.C., March 28, 2025 ...
Milestone Pharmaceuticals hit another bump in the road in its quest to get Cardamyst approved for paroxysmal supraventricular ...
Stocktwits on MSN9h
Milestone Pharmaceuticals Stock Plunges 60% After FDA Declines To Approve Its Cardamyst Nasal Spray – But Retail’s PositiveShares of Milestone Pharmaceuticals Inc. (MIST) traded 60% lower on Friday after the Food and Drug Administration (FDA) did ...
Zacks Small Cap Research on MSN16d
ACHV: 2Q:25 NDA SubmissionACHV READ THE FULL ACHV RESEARCH REPORT Achieve Life Sciences, Inc. (NASDAQ:ACHV) reported 2024 results sharing progress with the new drug application (NDA) for cytisinicline and narrowing its ...
December 2024, immediately following the approval of the world's first mesenchymal stromal cells clinical trial, the U.S. FDA ...
March 2023, a second NDA submission of the same product by Mesoblast encountered another rejection for lacking controlled trials with adult patients and ongoing CMC issues. These repeated ...
Dermata expects to announce topline results from its XYNGARI Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial by end of March 2025 -- The Company recently entered into a Clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback